ArticleAnnals of medicine and surgery (2012)2023
Systemic lupus erythematosus disease activity and neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio: a cross-sectional case-control study.
Article in Annals of medicine and surgery (2012), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.
- Pooled it
- Peripheral Blood Neutrophil-to-Lymphocyte Ratio Combined With Fibrinogen-to-Albumin Ratio Assists in Identifying Systemic Lupus Erythematosus Activity and Lupus Nephritis.APMIS : acta pathologica, microbiologica, et immunologica Scandinavica · 2026Article
- Article
- Assessing the relation between systemic lupus erythematosus and metabolic syndrome in Syria: a cross-sectional study.BMC rheumatology · 2025Article
- Correlation between CBC-derived inflammatory indicators and all-cause mortality with rheumatoid arthritis: a population-based study.Frontiers in medicine · 2025Article
- NLR (neutrophil to lymphocyte ratio), PLR (platelet to lymphocyte ratio), and SII (systemic immune-inflammation index) reflect disease activity and renal remission in patients with lupus nephritis.Frontiers in immunology · 2025Article
- The neutrophil-to-lymphocyte ratio as a surrogate marker for disease activity in systemic lupus erythematosus: a correlation study using the SLE-DAS.Therapeutic advances in musculoskeletal disease · 2025Article
- Successful treatment of refractory interstitial lung disease with cyclophosphamide and pirfenidone in a new onset of juvenile SLE: a case report.Annals of medicine and surgery (2012) · 2024Article
- Central neurological manifestations in a sample of Syrian patients with systemic lupus erythematosus: cross-sectional study.Annals of medicine and surgery (2012) · 2024Article
- Blood Composite Scores in Patients with Systemic Lupus Erythematosus.Biomedicines · 2023Article
- Potential Biomarkers for Disease Activity in Systemic Lupus Erythematosus.Current health sciences journalArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Systemic lupus erythematosus (SLE) is an autoimmune disease with unknown etiology. It involves multiple organs and presents as varying clinical manifestations such as renal involvement (nephritis) and hematological disorders. Materials and Methods: One hundred sixty people, divided equally into two groups: SLE patients, diagnosed according to the 2010 American College of Rheumatology/European League Against Rheumatism criteria, and healthy controls matched in age and gender, attending the University Hospitals between April 2019 and January 2021. White blood cells count, neutrophils count, lymphocytes count, platelet count, erythrocyte sedimentation rate, C-reactive protein, serum complements (C3 and C4), anti-double-stranded deoxyribonucleic acid, neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and the SLE disease activity by using Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) was compared between the patient group and the control group. Demographic data were collected from all participants, and data on the disease, including disease durations and disease activity, were only collected from the patients. Results: The age of the patients was 30.49±10.979 years, while it was 34.54±13.710 years in the control group ( Conclusion: The NLR and PLR are correlated with disease activity while also being cost-effective.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.